HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation.

Abstract
In patients referred for allogeneic hematopoietic stem cell transplantation (HSCT), iron overload is frequent and associated with increased morbidity and mortality. Both the evolution of iron overload after transplantation and its correlation with late posttransplantation events are unknown. We studied 290 patients undergoing myeloablative allogeneic HSCT between 2000 and 2009. Serum ferritin, transferrin saturation, transferrin, iron, and soluble transferrin receptor were determined regularly between 1 and 60 months after HSCT, and values were correlated with transplantation outcome. Ferritin levels peaked in the first 3 months posttransplantation and then decreased to normal values at 5 years. Transferrin saturation and iron behaved analogously, whereas transferrin and soluble transferrin receptor increased after an early nadir. Landmark survival analysis showed that hyperferritinemia had a detrimental effect on survival in all periods analyzed (0 to 6 months P < .001; 6 to 12 months P < .001; 1 to 2 years P = .02; 2 to 5 years P = .002). This effect was independent of red blood cell transfusion dependency and graft-versus-host disease. Similar trends were seen for other iron parameters. These data show the natural dynamics of iron parameters in the setting of allogeneic HSCT and provide evidence for a prognostic role of iron overload extending beyond the immediate posttransplantation period. Interventions to reduce excessive body iron might therefore be beneficial both before and after HSCT.
AuthorsSara C Meyer, Alix O'Meara, Andreas S Buser, André Tichelli, Jakob R Passweg, Martin Stern
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (Biol Blood Marrow Transplant) Vol. 19 Issue 3 Pg. 440-4 (Mar 2013) ISSN: 1523-6536 [Electronic] United States
PMID23089566 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Immunosuppressive Agents
  • Myeloablative Agonists
  • Receptors, Transferrin
  • Transferrin
  • Ferritins
  • Iron
Topics
  • Adolescent
  • Adult
  • Aged
  • Female
  • Ferritins (metabolism)
  • Graft vs Host Disease (drug therapy, immunology, mortality, pathology)
  • Hematologic Neoplasms (immunology, mortality, pathology, therapy)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Immunosuppressive Agents (pharmacology, therapeutic use)
  • Iron (metabolism)
  • Iron Overload (etiology, metabolism, mortality, pathology)
  • Male
  • Middle Aged
  • Myeloablative Agonists (pharmacology, therapeutic use)
  • Prognosis
  • Receptors, Transferrin (metabolism)
  • Retrospective Studies
  • Survival Analysis
  • Transferrin (metabolism)
  • Transplantation, Homologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: